Response and Survival with Immune Checkpoint Inhibitor in patients with advanced Urothelial Carcinoma and Histology Subtypes

Clinical Genitourinary Cancer, Journal Year: 2025, Volume and Issue: unknown, P. 102356 - 102356

Published: April 1, 2025

Language: Английский

---

Clinical impact of a subtype of urothelial carcinoma in nonmuscle-invasive bladder cancer

Japanese Journal of Clinical Oncology, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 22, 2024

Abstract Objective This study aimed to assess the oncological outcomes of subtype urothelial carcinoma (SUC), including divergent differentiation and histologic subtype, in comparison with those pure (PUC) nonmuscle-invasive bladder cancer. Methods We retrospectively evaluated patients who were initially treated transurethral resection tumor (TURBT) between March 2005 August 2020 at a single institution. Patients PUC SUC compared terms recurrence-free survival (RFS), progression-free (PFS), overall (OS). Results Out 853 enrolled patients, 783 (91.8%) 70 (8.2%) had SUC, respectively. presence was significantly associated old age, size (≥3 cm), higher pT1 rate, high grade, concomitant situ, lymphovascular invasion. RFS rates after TURBT did not differ groups. With median follow-up period 66 months (interquartile range, 38–103 months), time progression muscle invasion 6.9% 22.5 group, 22.9% 10.0 group. Moreover, incidence metastasis 4.6% 15.7% groups, The 5-year PFS (64.5% 81.9%, P < .001) OS (71.7% 86.2%, = .009) lower group than On multivariate analysis, independently predicted metastasis. Conclusion At initial diagnosis, we must pay more attention risk that

Language: Английский

---

Bladder cancer variants — one disease with many faces

Nature Reviews Urology, Journal Year: 2024, Volume and Issue: 21(9), P. 519 - 520

Published: April 22, 2024

Language: Английский

---